Evidence map›Paper›PMID 41687121›Full record

ArticleJournal of the American Chemical Society2026

Myxarylin: Total

Asfandyar Sikandar, Lana Vianey, Kai Schließmann, Qiyao Shen, C Logan Mackay, F P Jake Haeckl, Vlada B Urlacher, James H Naismith, Rolf Müller

Abstract read
In one paragraph

Article in Journal of the American Chemical Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Asfandyar SikandarHelmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Center for Infection Research (HZI), Saarbrücken, 66123, Germany.ORCID 0000-0002-6566-4022
Lana VianeyHelmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Center for Infection Research (HZI), Saarbrücken, 66123, Germany.
Kai SchließmannHelmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Center for Infection Research (HZI), Saarbrücken, 66123, Germany.
Qiyao ShenHelmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Center for Infection Research (HZI), Saarbrücken, 66123, Germany.
C Logan MackayThe Rosalind Franklin Institute, Harwell Campus, Didcot OX11 0QX, U.K.ORCID 0000-0003-1018-8353
F P Jake HaecklHelmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Center for Infection Research (HZI), Saarbrücken, 66123, Germany.ORCID 0000-0002-2776-5957
Vlada B UrlacherInstitute of Biochemistry, Heinrich-Heine University Düsseldorf, Düsseldorf 40225, Germany.ORCID 0000-0003-1312-4574
James H NaismithThe Rosalind Franklin Institute, Harwell Campus, Didcot OX11 0QX, U.K.
Rolf MüllerHelmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Center for Infection Research (HZI), Saarbrücken, 66123, Germany.ORCID 0000-0002-1042-5665

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biarylitides are a new class of ribosomally synthesized and post-translationally modified peptides (RiPPs) featuring the smallest reported precursor peptide and cytochrome P450-mediated cross-links. Here, we report the complete

Identifiers

PMID41687121
PMCPMC12951456

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.